NEUROTOXIN COMPONENT TREATMENT FOR SPASTICITY
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
1 . A method for treating spasticity, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component from a single serotype of a botulinum toxin, to thereby treat the spasticity, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting Clostridium botulinum.
2 . The method of claim 1 wherein the single botulinum toxin serotype, from which the neurotoxic component administered is purified, is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
3 . The method of claim 2 , wherein the botulinum toxin is botulinum toxin type A.
4 . The method of claim 1 , wherein between about 1 unit and about 250 units of the neurotoxic component of the botulinum toxin is administered.
5 . The method of claim 1 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
6 . The method of claim 1 , wherein the spasticity is a post-stroke spasticity.
7 . The method of claim 1 , wherein the spasticity is secondary to a brain injury.
8 . The method of claim 1 , wherein the spasticity is secondary to a spinal cord injury.
9 . The method of claim 1 , wherein the neurotoxic component is administered by local administration.
10 . A method for treating spasticity, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a botulinum toxin type A to thereby treat the spasticity, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin obtained by fermenting a Clostridium botulinum bacterium.
11 . The method of claim 10 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
12 . The method of claim 10 , wherein the spasticity is a post-stroke spasticity.
13 . The method of claim 10 , wherein the spasticity is secondary to a brain injury.
14 . The method of claim 10 , wherein the spasticity is secondary to a spinal cord injury.
15 . A method for treating post-stroke spasticity, the method comprising the step of administering to a patient a therapeutically effective amount of the neurotoxic component of only a botulinum toxin type A to thereby treat the post-stroke spasticity, wherein the neurotoxic component administered to the patient has been purified from a botulinum toxin type A obtained by fermenting a Clostridium botulinum bacterium.
16 . The method of claim 15 , wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
17 . The method of claim 15 , wherein the neurotoxic component is administered by local administration.